Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 3
2015 1
2020 1
2021 1
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Cationic Porphyrin-Based Ionic Nanomedicines for Improved Photodynamic Therapy.
Forson M, Bashiru M, Macchi S, Singh S, Anderson AD, Sayyed S, Ishtiaq A, Griffin R, Ali N, Oyelere AK, Berry B, Siraj N. Forson M, et al. ACS Appl Bio Mater. 2023 Dec 18;6(12):5662-5675. doi: 10.1021/acsabm.3c00809. Epub 2023 Dec 8. ACS Appl Bio Mater. 2023. PMID: 38063308 Free PMC article.
Doxorubicin-Based Ionic Nanomedicines for Combined Chemo-Phototherapy of Cancer.
Bashiru M, Macchi S, Forson M, Khan A, Ishtiaq A, Oyebade A, Jalihal A, Ali N, Griffin RJ, Oyelere AK, Hooshmand N, Siraj N. Bashiru M, et al. Among authors: forson m. ACS Appl Nano Mater. 2024 Jan 26;7(2):2176-2189. doi: 10.1021/acsanm.3c05464. Epub 2024 Jan 17. ACS Appl Nano Mater. 2024. PMID: 38410412 Free PMC article.
Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.
Phillips RO, Robert J, Abass KM, Thompson W, Sarfo FS, Wilson T, Sarpong G, Gateau T, Chauty A, Omollo R, Ochieng Otieno M, Egondi TW, Ampadu EO, Agossadou D, Marion E, Ganlonon L, Wansbrough-Jones M, Grosset J, Macdonald JM, Treadwell T, Saunderson P, Paintsil A, Lehman L, Frimpong M, Sarpong NF, Saizonou R, Tiendrebeogo A, Ohene SA, Stienstra Y, Asiedu KB, van der Werf TS; study team. Phillips RO, et al. Lancet. 2020 Apr 18;395(10232):1259-1267. doi: 10.1016/S0140-6736(20)30047-7. Epub 2020 Mar 12. Lancet. 2020. PMID: 32171422 Free PMC article. Clinical Trial.
Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
Phillips RO, Sarfo FS, Abass MK, Abotsi J, Wilson T, Forson M, Amoako YA, Thompson W, Asiedu K, Wansbrough-Jones M. Phillips RO, et al. Among authors: forson m. Antimicrob Agents Chemother. 2014;58(2):1161-6. doi: 10.1128/AAC.02165-13. Epub 2013 Dec 9. Antimicrob Agents Chemother. 2014. PMID: 24323473 Free PMC article.
Combined inflammatory and metabolic defects reflected by reduced serum protein levels in patients with Buruli ulcer disease.
Phillips RO, Sarfo FS, Landier J, Oldenburg R, Frimpong M, Wansbrough-Jones M, Abass K, Thompson W, Forson M, Fontanet A, Niang F, Demangel C. Phillips RO, et al. Among authors: forson m. PLoS Negl Trop Dis. 2014 Apr 10;8(4):e2786. doi: 10.1371/journal.pntd.0002786. eCollection 2014 Apr. PLoS Negl Trop Dis. 2014. PMID: 24722524 Free PMC article.
11 results